Oxford Gene Technology has announced the launch of its newly updated NGS SureSeq™ CLL + CNV V3 Panel. This new panel was designed to offer users more comprehensive variant detection to improve confidence in classification of CLL research samples to strengthen the understanding of CLL progression. Compared to its predecessor, the company states the new panel, coupled with OGT’s complimentary NGS analysis software, Interpret, demonstrated a 38% increase in CNV detection, highlighting the improved assay performance.
